Search Results for "Where To Buy Pirfenidone"

04:19 EST 24th November 2014 | BioPortfolio

Matching Channels

None

Matching News

Pirfenidone and Fibrocyte Accumulation in Pulmonary Fibrosis

Does pirfenidone inhibit fibrocyte pool size in the lungs of bleomycin-treated mice? Respiratory Research

US breakthrough status for InterMune’s pirfenidone

US biotech firm InterMune’s Esbriet (pirfenidone) has been granted Breakthrough Therapy designation from the US Food and Drug Administration. The announcement of Friday caused a 2.7% rise to $41.70 ...

FDA Grants breakthough therapy designation for InterMune’s pirfenidone

InterMune has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for its pirfenidone, an investigational treatment for adult patients with idiopathic pulmonary fi...

FDA accepts NDA for InterMune's pirfenidone

FDA accepted for review a resubmitted NDA from InterMune Inc. (NASDAQ:ITMN) for pirfenidone to treat idiopathic pulmonary fibrosis (IPF). The agency designated the NDA a Class 2 resubmission, with a N...

Roche’s Pirfenidone Bet Validates China Venture

China was probably not a major consideration in Roche’s $8 billion-plus bet on U.S. biotech InterMune and its mainstay product pirfenidone, but the figure paid for the acquisition may be seen as val...

InterMune resubmits pirfenidone NDA

InterMune Inc. (NASDAQ:ITMN) resubmitted an NDA to FDA for pirfenidone to treat adults with idiopathic pulmonary fibrosis (IPF). In 2010, FDA issued a complete response letter asking for an additional...

InterMune Receives FDA Breakthrough Therapy Designation for Pirfenidone, an Investigational Treatment for IPF

BRISBANE, Calif., July 17, 2014 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that pirfenidone has been granted Breakthrough Therapy Designation from the U.S. Food and Drug Administra...

FDA Approves Esbriet (pirfenidone) for Idiopathic Pulmonary Fibrosis

October 15, 2014 -- The U.S. Food and Drug Administration today approved Esbriet (pirfenidone) for the treatment of idiopathic pulmonary fibrosis (IPF). Idiopathic pulmonary fibrosis is a condition i...

Matching PubMed Articles

Pirfenidone attenuates the IL-1β-induced hyaluronic acid increase in orbital fibroblasts from patients with thyroid-associated ophthalmopathy.

Purpose:This study aimed to investigate the effect of pirfenidone on the interleukin (IL)-1β-induced hyaluronic acid (HA) increase in orbital fibroblasts from patients with thyroid-associated ophthal...

Pirfenidone: an update on clinical trial data and insights from everyday practice.

Pirfenidone is an orally active, small molecule that inhibits synthesis of profibrotic and inflammatory mediators. It was approved for the treatment of adults with mild-to-moderate idiopathic pulmonar...

Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events.

Pirfenidone is currently the only approved therapy for idiopathic pulmonary fibrosis, following studies demonstrating that treatment reduces the decline in lung function and improves progression-free ...

Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

Pirfenidone, an oral anti-inflammatory, antifibrotic agent with activity in idiopathic pulmonary fibrosis, may mediate anti-tumor activity in neurofibromatosis type 1 (NF1) and plexiform neurofibromas...

Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis.

Idiopathic pulmonary fibrosis (IPF) is a devastating chronic fibrotic lung disease. Although the precise cause of the disease is still unknown, recent studies have shown that the pathogenesis of pulmo...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement